Moreover, and in agreement with preceding data, loss of SETD1A also restored Olaparib-induced RAD51 foci formation and thus HR activity in both BRCA1-mutated ovarian and breast cancer cell lines and in ATM-mutated lung cancer cells (Fig. 4g–i). Here, RAD51 is linked to breast cancer.